147 related articles for article (PubMed ID: 38010609)
1. A comparison of the incidence of ≥ grade 2 radiation pneumonitis between intensity-modulated radiotherapy and three-dimensional conformal radiotherapy in patients with unresectable non-small cell lung cancer treated with durvalumab after concurrent chemoradiotherapy.
Masuo M; Shinohara E; Kitano M; Maruta R; Chonabayashi S; Endo S; Matumoto S; Nishiyama N; Machitori Y; Kobayashi M
Jpn J Clin Oncol; 2024 Mar; 54(3):312-318. PubMed ID: 38010609
[TBL] [Abstract][Full Text] [Related]
2. The efficacy profiles of concurrent chemoradiotherapy with intensity-modulated radiotherapy followed by durvalumab in patients with unresectable stage III non-small cell lung cancer: A multicenter retrospective cohort study.
Takeda Y; Kusaba Y; Tsukita Y; Uemura Y; Miyauchi E; Yamamoto T; Mayahara H; Hata A; Nakayama H; Tanaka S; Uchida J; Usui K; Toyoda T; Tamiya M; Morimoto M; Oya Y; Kodaira T; Jingu K; Sugiura H
Clin Transl Radiat Oncol; 2022 Nov; 37():57-63. PubMed ID: 36065360
[TBL] [Abstract][Full Text] [Related]
3. Intensity-modulated radiation therapy with concurrent chemotherapy followed by durvalumab for stage III non-small cell lung cancer: A multi-center retrospective study.
Tsukita Y; Yamamoto T; Mayahara H; Hata A; Takeda Y; Nakayama H; Tanaka S; Uchida J; Usui K; Toyoda T; Tamiya M; Morimoto M; Oya Y; Kodaira T; Miyauchi E; Jingu K; Sugiura H
Radiother Oncol; 2021 Jul; 160():266-272. PubMed ID: 34023330
[TBL] [Abstract][Full Text] [Related]
4. Incidence and Risk Factors of Symptomatic Radiation Pneumonitis in Non-Small-Cell Lung Cancer Patients Treated with Concurrent Chemoradiotherapy and Consolidation Durvalumab.
Shintani T; Kishi N; Matsuo Y; Ogura M; Mitsuyoshi T; Araki N; Fujii K; Okumura S; Nakamatsu K; Kishi T; Atsuta T; Sakamoto T; Narabayashi M; Ishida Y; Sakamoto M; Fujishiro S; Katagiri T; Kim YH; Mizowaki T
Clin Lung Cancer; 2021 Sep; 22(5):401-410. PubMed ID: 33678582
[TBL] [Abstract][Full Text] [Related]
5. Durvalumab after chemoradiotherapy for locally advanced non-small cell lung cancer prolonged distant metastasis-free survival, progression-free survival and overall survival in clinical practice.
Yamamoto T; Tsukita Y; Katagiri Y; Matsushita H; Umezawa R; Ishikawa Y; Takahashi N; Suzuki Y; Takeda K; Miyauchi E; Saito R; Katsuta Y; Kadoya N; Jingu K
BMC Cancer; 2022 Apr; 22(1):364. PubMed ID: 35379201
[TBL] [Abstract][Full Text] [Related]
6. Dosimetry and Biochemical Comparison of Early Radiation-Induced Lung Toxicity in Breast Cancer Patients Treated with 3D-CRT and IMRT: the Role of Serum Interleukin-6 and Pulmonary Surfactant Protein-D.
Mahmoud Hewala TI; El-Benhawy SA; Elwany YN; Hammoury SI; Saeda MA
Asian Pac J Cancer Prev; 2024 May; 25(5):1707-1713. PubMed ID: 38809643
[TBL] [Abstract][Full Text] [Related]
7. Acute hospitalizations after proton therapy versus intensity-modulated radiotherapy for locally advanced non-small cell lung cancer in the durvalumab era.
Iocolano M; Yegya-Raman N; Friedes C; Wang X; Kegelman T; Lee SH; Duan L; Li B; Levin WP; Cengel KA; Konski A; Langer CJ; Cohen RB; Sun L; Aggarwal C; Doucette A; Xiao Y; Kevin Teo BK; O'Reilly S; Zou W; Bradley JD; Simone CB; Feigenberg SJ
Cancer; 2024 Jun; 130(11):2031-2041. PubMed ID: 38294959
[TBL] [Abstract][Full Text] [Related]
8. Durvalumab in combination with chemoradiotherapy for patients with unresectable stage III non-small-cell lung cancer: Results from the phase 1 CLOVER study.
Kim DW; Chul Cho B; Pachipala K; Kim SW; Wang CL; Chang GC; Ahn MJ; Alvarez R; Chiu CH; Trigo J; Estival A; Karam SD; O'Brien C; Gowda H; Jiang H; Bauman JE
Lung Cancer; 2024 Apr; 190():107530. PubMed ID: 38471416
[TBL] [Abstract][Full Text] [Related]
9. Impact of Intensity-Modulated Radiation Therapy Technique for Locally Advanced Non-Small-Cell Lung Cancer: A Secondary Analysis of the NRG Oncology RTOG 0617 Randomized Clinical Trial.
Chun SG; Hu C; Choy H; Komaki RU; Timmerman RD; Schild SE; Bogart JA; Dobelbower MC; Bosch W; Galvin JM; Kavadi VS; Narayan S; Iyengar P; Robinson CG; Wynn RB; Raben A; Augspurger ME; MacRae RM; Paulus R; Bradley JD
J Clin Oncol; 2017 Jan; 35(1):56-62. PubMed ID: 28034064
[TBL] [Abstract][Full Text] [Related]
10. Impact of radiation techniques on lung toxicity in patients with mediastinal Hodgkin's lymphoma.
Pepper NB; Oertel M; Kittel C; Kröger KJ; Elsayad K; Haverkamp U; Eich HT
Strahlenther Onkol; 2021 Jan; 197(1):56-62. PubMed ID: 32945894
[TBL] [Abstract][Full Text] [Related]
11. Predicting factors of symptomatic radiation pneumonitis induced by durvalumab following concurrent chemoradiotherapy in locally advanced non-small cell lung cancer.
Mayahara H; Uehara K; Harada A; Kitatani K; Yabuuchi T; Miyazaki S; Ishihara T; Kawaguchi H; Kubota H; Okada H; Ninomaru T; Shindo C; Hata A
Radiat Oncol; 2022 Jan; 17(1):7. PubMed ID: 35033139
[TBL] [Abstract][Full Text] [Related]
12. Phase II Study of Durvalumab Immediately after Completion of Chemoradiotherapy in Unresectable Stage III Non-small Cell Lung Cancer: TORG1937 (DATE Study).
Nakamichi S; Kubota K; Misumi T; Kondo T; Murakami S; Shiraishi Y; Imai H; Harada D; Isobe K; Itani H; Takata S; Wakui H; Misumi Y; Ikeda S; Asao T; Furuya N; Hosokawa S; Kobayashi Y; Takiguchi Y; Okamoto H
Clin Cancer Res; 2024 Mar; 30(6):1104-1110. PubMed ID: 38165684
[TBL] [Abstract][Full Text] [Related]
13. Initial evaluation of treatment-related pneumonitis in advanced-stage non-small-cell lung cancer patients treated with concurrent chemotherapy and intensity-modulated radiotherapy.
Yom SS; Liao Z; Liu HH; Tucker SL; Hu CS; Wei X; Wang X; Wang S; Mohan R; Cox JD; Komaki R
Int J Radiat Oncol Biol Phys; 2007 May; 68(1):94-102. PubMed ID: 17321067
[TBL] [Abstract][Full Text] [Related]
14. Clinical features and risk factors for interstitial lung disease spreading in low-dose irradiated areas after definitive radiotherapy with or without durvalumab consolidation therapy for patients with non-small cell lung cancer.
Sakagami M; Inokuchi H; Mukumoto N; Itoyama H; Hamaura N; Yamagishi M; Mukumoto N; Matsuda S; Kabata D; Shibuya K
Radiat Oncol; 2023 May; 18(1):87. PubMed ID: 37217919
[TBL] [Abstract][Full Text] [Related]
15. Potential benefits of volumetric modulated arc therapy to reduce the incidence of ≥ grade 2 radiation pneumonitis in radiotherapy for locally advanced non-small cell lung cancer patients.
Imano N; Kimura T; Kawahara D; Nishioka R; Fukumoto W; Kawano R; Kubo K; Katsuta T; Takeuchi Y; Nishibuchi I; Murakami Y; Horimasu Y; Masuda T; Fujitaka K; Hattori N; Nagata Y
Jpn J Clin Oncol; 2021 Dec; 51(12):1729-1735. PubMed ID: 34625805
[TBL] [Abstract][Full Text] [Related]
16. Propensity score-based comparison of survival and radiation pneumonitis after definitive chemoradiation for esophageal cancer: Intensity-modulated radiotherapy versus three-dimensional conformal radiotherapy.
Lan K; Zhu J; Zhang J; Zhou S; Yang Y; Feng Z; Zhang L; Wang S; Xi M
Radiother Oncol; 2020 Aug; 149():228-235. PubMed ID: 32474127
[TBL] [Abstract][Full Text] [Related]
17. Incidence and dose-volume relationship of radiation pneumonitis after concurrent chemoradiotherapy followed by durvalumab for locally advanced non-small cell lung cancer.
Saito S; Abe T; Kobayashi N; Aoshika T; Ryuno Y; Igari M; Hirai R; Kumazaki Y; Miura Y; Kaira K; Kagamu H; Noda SE; Kato S
Clin Transl Radiat Oncol; 2020 Jul; 23():85-88. PubMed ID: 32529055
[TBL] [Abstract][Full Text] [Related]
18. New dose constraint reduces radiation-induced fatal pneumonitis in locally advanced non-small cell lung cancer patients treated with intensity-modulated radiotherapy.
Khalil AA; Hoffmann L; Moeller DS; Farr KP; Knap MM
Acta Oncol; 2015; 54(9):1343-9. PubMed ID: 26198657
[TBL] [Abstract][Full Text] [Related]
19. Intensity-Modulated Radiotherapy versus Three-Dimensional Conformal Radiotherapy in Definitive Chemoradiotherapy for Cervical Esophageal Squamous Cell Carcinoma: Comparison of Survival Outcomes and Toxicities.
Chen NB; Qiu B; Zhang J; Qiang MY; Zhu YJ; Wang B; Guo JY; Cai LZ; Huang SM; Liu MZ; Li Q; Hu YH; Li QW; Liu H
Cancer Res Treat; 2020 Jan; 52(1):31-40. PubMed ID: 31048664
[TBL] [Abstract][Full Text] [Related]
20. The incidence of and risk factors for radiation pneumonitis in patients treated with simultaneous bevacizumab and thoracic radiotherapy.
Chen F; Niu J; Wang M; Zhu H; Guo Z
Radiat Oncol; 2024 May; 19(1):67. PubMed ID: 38816745
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
